Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Cross-protection is crucial for prophylactic HPV vaccination.

Lehtinen M.

Lancet Infect Dis. 2012 Oct;12(10):742-3. doi: 10.1016/S1473-3099(12)70203-7. Epub 2012 Aug 22. No abstract available.

PMID:
22920952
2.

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.

Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M.

Lancet Infect Dis. 2012 Oct;12(10):781-9. doi: 10.1016/S1473-3099(12)70187-1. Epub 2012 Aug 22. Review.

PMID:
22920953
3.

Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.

Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.

Vaccine. 2013 Aug 20;31(37):3922-7. doi: 10.1016/j.vaccine.2013.06.044. Epub 2013 Jun 24.

PMID:
23806241
4.

Postlicensure monitoring of HPV vaccination programmes.

Markowitz LE, Hariri S.

Lancet Infect Dis. 2014 Oct;14(10):904-5. doi: 10.1016/S1473-3099(14)70871-0. Epub 2014 Aug 5. No abstract available.

PMID:
25107681
5.

Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.

Szarewski A.

Expert Rev Vaccines. 2012 Jun;11(6):645-57. doi: 10.1586/erv.12.42.

PMID:
22873123
6.

Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.

Herrero R.

J Infect Dis. 2009 Apr 1;199(7):919-22. doi: 10.1086/597308. No abstract available.

PMID:
19236278
7.

Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.

Stanley M, Gissmann L, Nardelli-Haefliger D.

Vaccine. 2008 Aug 19;26 Suppl 10:K62-7. doi: 10.1016/j.vaccine.2008.05.066. Review.

PMID:
18847558
8.

Measuring serum antibody to human papillomavirus following infection or vaccination.

Frazer IH.

Gynecol Oncol. 2010 Jun;118(1 Suppl):S8-11. doi: 10.1016/j.ygyno.2010.04.003. Review.

PMID:
20494221
9.

[Developments in HPV vaccination].

de Melker H, Kenter G, van Rossum T, Conyn-van Spaendonck M.

Ned Tijdschr Geneeskd. 2012;156(47):A5410. Review. Dutch.

PMID:
23171565
10.

Cross protection against HPV might prevent type replacement.

Verdenius I, Groner JA, Harper DM.

Lancet Infect Dis. 2013 Mar;13(3):195. doi: 10.1016/S1473-3099(13)70024-0. No abstract available.

PMID:
23427887
11.

Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening.

Coupé VM, Bogaards JA, Meijer CJ, Berkhof J.

Vaccine. 2012 Feb 27;30(10):1813-22. doi: 10.1016/j.vaccine.2012.01.001. Epub 2012 Jan 10.

PMID:
22240341
12.
13.

Prophylactic HPV vaccination for the prevention of cervical cancer.

Hernandez BY.

Hawaii Med J. 2007 Jul;66(7):190-1. No abstract available.

PMID:
17879858
14.

Human papillomavirus: current status and issues of vaccination.

Malik H, Khan FH, Ahsan H.

Arch Virol. 2014 Feb;159(2):199-205. Review.

PMID:
24022639
15.

HPV vaccination: the beginning of the end of cervical cancer? - A Review.

Lepique AP, Rabachini T, Villa LL.

Mem Inst Oswaldo Cruz. 2009 Feb;104(1):1-10. Review.

16.

Human papillomavirus vaccine: widening the scope for cancer prevention.

No JH, Kim MK, Jeon YT, Kim YB, Song YS.

Mol Carcinog. 2011 Apr;50(4):244-53. doi: 10.1002/mc.20657. Review.

PMID:
21465574
17.

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G; HPV-010 Study Group.

Hum Vaccin. 2009 Oct;5(10):705-19. Epub 2009 Oct 14.

PMID:
19684472
18.

HPV genotype replacement: too early to tell.

Pons-Salort M, Thiébaut AC, Guillemot D, Favre M, Delarocque-Astagneau E.

Lancet Infect Dis. 2013 Dec;13(12):1012. doi: 10.1016/S1473-3099(13)70302-5. No abstract available.

PMID:
24262294
19.

Age for HPV vaccination.

Harper DM, Paavonen J.

Vaccine. 2008 Mar 14;26 Suppl 1:A7-11. Review.

PMID:
18642467
20.

Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence.

Bonanni P, Boccalini S, Bechini A.

Vaccine. 2009 May 29;27 Suppl 1:A46-53. doi: 10.1016/j.vaccine.2008.10.085. Review.

PMID:
19480962

Supplemental Content

Support Center